Amgen to buy Horizon Therapeutics in $26.4B deal

Article

Amgen, biotech drug developer, said it will pay $116.50 in cash for each share of Horizon, which makes a thyroid eye disease treatment that generated more than $1 billion in its first full year on the market.

The deal offers Amgen another chance to build its portfolio of rare-disease treatments after it closed in October a roughly $3.7 billion acquisition of ChemoCentryx, which focuses on autoimmune disease drugs.

Horizon Therapeutics PLC, based in Dublin, Ireland, develops potential treatments for rare, autoimmune and severe inflammatory diseases. Its best-seller, Tepezza, is only approved in the United States and treats eye bulging and double vision from thyroid eye disease.

Read more at Associated Press

Recent Videos
Ted Sweetser
Ted Sweetser
Ted Sweetser
Amy Hessels, Bayer
Related Content